Cerenome (PSTV) Short-term Investments (2024 - 2026)

Plus Therapeutics (PSTV) has reported Short-term Investments for 3 consecutive years, with $12.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments changed N/A year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $12.1 million (changed N/A YoY), while the FY2025 annual figure was $4.4 million, up 23.4% from the prior year.
• Short-term Investments rose to $12.1 million in Q1 2026 per PSTV's latest filing, from $4.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $12.1 million in Q1 2026 and bottomed at $2.1 million in Q1 2024.
• Historically, Short-term Investments has averaged $4.6 million across 3 years, with a median of $3.5 million in 2024.
• On a YoY basis, Short-term Investments climbed as much as 31.88% in 2025 and fell as far as 7.1% in 2025.
• Plus Therapeutics' Short-term Investments stood at $3.5 million in 2024, then climbed by 23.4% to $4.4 million in 2025, then soared by 177.59% to $12.1 million in 2026.
• Business Quant data shows PSTV's Short-term Investments at $12.1 million in Q1 2026, $4.4 million in Q4 2025, and $3.3 million in Q3 2025.